Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.45 |
| ▸ | PEPD | P12955 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016475 | 0.87 | SMN1; SMN2 (0.45) | ALDH1A1NPC1TRPV1MAPTMEN1 | |
| SCHEMBL2370528 | 0.84 | TRPV1 (0.46) | ALDH1A1NPC1TRPV1MAPTMEN1 | |
| SCHEMBL1991350 | 0.83 | CYP17A1 (0.43) | TRPV1 | |
| SCHEMBL443381 | 0.81 | TRPV1 (0.44) | NPC1TRPV1GAAMEN1KMT2A | |
| SCHEMBL1832033 | 0.80 | PARP10 (0.41) | ALDH1A1MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL2369624 | 0.80 | EPHX1 (0.50) | ALDH1A1NPC1 | |
| SCHEMBL6610808 | 0.80 | CYP17A1 (0.49) | — | |
| SCHEMBL3519257 | 0.80 | TRPV1 (0.32) | KIF11ALDH1A1TRPV1HSD17B10 | |
| SCHEMBL2369397 | 0.79 | KMT2A (0.51) | ALDH1A1NPC1TRPV1MAPTMEN1 | |
| SCHEMBL1832517 | 0.78 | EPHX1 (0.57) | ALDH1A1NPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| WO-2013049332-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2010059838-A2 | PDE4 INHIBITORS SELECTIVE FOR THE LONG FORM OF PDE4 FOR TREATING INFLAMMATION AND AVOIDING SIDE EFFECTS | DECODE GENETICS EHF (IS) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059836-A1 | SUBSTITUTED AZA-BRIDGED BICYCLICS FOR CARDIOVASCULAR AND CNS DISEASE | DECODE GENETICS EHF (IS) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | MGLL, PNLIP, LIPC | KIF11 2691/4885PEPD 292/4885ALDH1A1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.